Rabies: a brief note on diagnostics and prophylactics
Аннотация
Rabies remains a formidable global public health challenge, attributable to viruses of the genus Lyssavirus . Control efforts have progressed markedly through the introduction of inactivated vaccines, rabies immunoglobulin (RIG), and monoclonal antibodies (mAbs), which collectively provide both pre- and post-exposure prophylaxis (PrEP and PEP). In low-resource environments, however, PEP implementation is hindered by the lack of highly sensitive diagnostic assays. At present, the gold-standard techniques endorsed by the World Organization for Animal Health (WOAH) and the World Health Organization (WHO) — namely the Rapid Fluorescent Focus Inhibition Test (RFFIT) and the Fluorescent Antibody Virus Neutralization (FAVN) assay — are employed to quantify rabies virus neutralizing antibody (VNA) titers. These assays, nonetheless, are labor-intensive, time-consuming, and necessitate handling of live virus. This review elucidates emerging methodologies for antibody quantification against rabies virus. Notably, the recent advancement of an Enzyme-Linked Immunosorbent Assay (ELISA) — characterized by rapid turnaround, high specificity and sensitivity, cost-effectiveness, and scalability has significantly enhanced detection of antibodies directed against the rabies virus glycoprotein. We also discuss the principle technical obstacles encountered during the assay development. Looking forward, these innovations are poised to improve both the accuracy and throughput of rabies serology, thereby streamlining efficacy evaluations and prophylaxis monitoring, and ultimately bolstering global rabies control and eradication initiatives.